Previous work has shown that p110α isoform-specific PI3K inhibitors can suppress Pik3ca mutant prostate cancer, whereas a p110β/δ inhibitor, or combined p110α/β blockade improves therapeutic outcome in Pten-deficient (p110β-dependent) prostate cancers [13,52,53]. Here, PIK3CG is linked to prostate carcinoma.